Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApoGraft for GvHD Prevention in Haplo-HSCT
NCT04006652Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ApoGraft in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Safety and tolerability of ApoGraft as measured by adverse events related to ApoGraft product at 1 year. Started Dec 2020; status: terminated.
02
Drugs
ApoGraft
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04006652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006652.